Description
AMG 232 is a potent, selective, orally bioavailable MDM2-p53 inhibitor with Kd of 0.045nM, inhibits SJSA-1 cell proliferation with IC50 of 9.1nM; robustly induces p53 activity, leading to cell-cycle arrest and inhibition of tumor cell proliferation; significantly inhibits tumor growth in SJSA-1 osteosarcoma xenograft model with ED50 of 9.1mg/kg, also showsignificantly superior antitumor efficacy chombined with chemotherapies in vivo, enhances radiosensitivity via inhibition of damage repair signaling. Skin Cancer Phase 2 Clinical